^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Antioxidant

    Related drugs:
    3d
    Efficacy and Safety of Idebenone Combined With Escitalopram in Post-stroke Depression: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (ChiCTR2500111442)
    P4, N=216, Not yet recruiting, Xuanwu Hospital Capital Medical University; Xuanwu Hospital Capital Medical University
    New P4 trial
    7d
    Cerebral Hemodynamic Effects of Oxygen and Antioxidants (CHEOXANT) (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Erasme University Hospital
    New trial
    8d
    Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors (clinicaltrials.gov)
    P1, N=44, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Feb 2030 --> Jan 2031 | Trial primary completion date: Feb 2030 --> Jan 2031
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cisplatin
    17d
    A Study of Acute Myocardial Infarction Using FDY-5301 (clinicaltrials.gov)
    P2, N=120, Completed, Faraday Pharmaceuticals, Inc. | Phase classification: P2a --> P2
    Phase classification
    21d
    MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis (clinicaltrials.gov)
    P2, N=79, Active, not recruiting, University of Edinburgh | Recruiting --> Active, not recruiting | N=206 --> 79 | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    25d
    Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis (clinicaltrials.gov)
    P2, N=0, Withdrawn, University of Edinburgh | N=120 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    25d
    The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults (clinicaltrials.gov)
    P2, N=60, Recruiting, UConn Health | Trial completion date: Jul 2027 --> Feb 2028 | Trial primary completion date: Sep 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    25d
    Probiotic Effects in Type 2 Diabetes (clinicaltrials.gov)
    P=N/A, N=77, Completed, Ege University
    New trial
    29d
    Thermotolerance induced by non-lethal heat shock at 40 °C is activated by mitochondrial ROS and is Nrf2-dependent. (PubMed, Arch Biochem Biophys)
    Mitochondrial ROS were found to be essential in mediating Nrf2-dependent thermotolerance, because MitoQ treatment prior to exposure to 40 °C reduced Nrf2 levels and dissipated the subsequent protective effect of thermotolerance against toxicity at 42 °C. Our study demonstrates that specific sources of ROS had biologically different implications in activating Nrf2, underlining potential therapeutic targets that may contribute to thermotolerance in anticancer treatments.
    Journal
    |
    NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    1m
    Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Nacuity Pharmaceuticals, Inc. | Trial completion date: Aug 2025 --> Apr 2026
    Trial completion date
    1m
    NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Nacuity Pharmaceuticals, Inc. | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    1m
    Composite Dietary Antioxidant Index and Metabolic Health in Overweight/Obesity in U.S. Adults (clinicaltrials.gov)
    P=N/A, N=38646, Completed, University-Town Hospital of Chongqing Medical University
    New trial